Related references
Note: Only part of the references are listed.The Rise of Molecular Glues
Stuart L. Schreiber
CELL (2021)
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Tyler B. Faust et al.
NATURE CHEMICAL BIOLOGY (2020)
Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
Dirksen E. Bussiere et al.
NATURE CHEMICAL BIOLOGY (2020)
Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library
Chelsea E. Powell et al.
ACS CHEMICAL BIOLOGY (2020)
Bardoxolone conjugation enables targeted protein degradation of BRD4
Bingqi Tong et al.
SCIENTIFIC REPORTS (2020)
Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons
Mary E. Matyskiela et al.
ACS CHEMICAL BIOLOGY (2020)
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells
Lukasz Skalniak et al.
FEBS JOURNAL (2019)
Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
Carl C. Ward et al.
ACS CHEMICAL BIOLOGY (2019)
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Jessica N. Spradlin et al.
NATURE CHEMICAL BIOLOGY (2019)
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Xiaoyu Zhang et al.
NATURE CHEMICAL BIOLOGY (2019)
Development of selective small molecule MDM2 degraders based on nutlin
Bo Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
Jiuling Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
Nobumichi Ohoka et al.
ACS CHEMICAL BIOLOGY (2019)
Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction
Constantinos G. Neochoritis et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines et al.
CANCER RESEARCH (2019)
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E. Matyskiela et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders
Mette Ishoey et al.
ACS CHEMICAL BIOLOGY (2018)
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Mengchen Lu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
Katherine A. Donovan et al.
ELIFE (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
Jian An et al.
NATURE COMMUNICATIONS (2017)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Georg Petzold et al.
NATURE (2016)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development
Daqing Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Exhaustive Fluorine Scanning toward Potent p53-Mdm2 Antagonists
Yijun Huang et al.
CHEMMEDCHEM (2012)
Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
Dennis L. Buckley et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
Yukihiro Itoh et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction
Ke Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
